Press Releases

Date Title and Summary Additional Formats
Toggle Summary Harvard Bioscience Presents Data, Symposium Session and New Products at Neuroscience 2018
HOLLISTON, Mass. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, is presenting its new neuroscience products and applications for preclinical life science research at
View HTML
Toggle Summary Harvard Bioscience Reports Third Quarter 2018 Financial Results
-Reports GAAP and adjusted non-GAAP revenue of $28.6 million and $28.7 million , respectively, an increase of 53% and 15%, respectively- HOLLISTON, Mass. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a
View HTML
Toggle Summary Harvard Bioscience Names Kam Unninayar as Chief Financial Officer
Seasoned Financial Executive With More Than a Decade in Global Life Science Instrumentation, Will Begin on November 26 HOLLISTON, Mass. , Oct. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience , Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of
View HTML
Toggle Summary Harvard Bioscience Schedules Third Quarter 2018 Conference Call for October 25 at 4:30 PM ET
HOLLISTON, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its third quarter 2018 after market trading hours on Thursday, October 25,
View HTML
Toggle Summary Harvard Bioscience Announces Management Change
CFO Resigns to Pursue New Opportunity HOLLISTON, Mass. , Aug. 22, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, today announced the resignation of Robert E.
View HTML
Toggle Summary Harvard Bioscience Reports Second Quarter 2018 Financial Results
-Reports record GAAP and adjusted non-GAAP revenue of $31.5 million and $31.6 million, respectively, an increase of 66% and 25%, respectively- HOLLISTON, Mass. , July 26, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO) (the “Company”), a global developer, manufacturer and marketer
View HTML
Toggle Summary Harvard Bioscience Schedules Second Quarter 2018 Conference Call for July 26 at 4:30 PM ET
HOLLISTON, Mass. , July 19, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), a global developer, manufacturer and marketer of a broad range of solutions to advance life science, will announce results for its second quarter 2018 after market trading hours on Thursday, July 26, 2018 .
View HTML
Toggle Summary Harvard Bioscience Subsidiary Data Sciences International Launches Two Telemetry Implants For Measuring Continuous Blood Glucose
PhysioTel™ Digital M0G and M1G: Designed to Improve Animal Welfare in Large Animal Models ST. PAUL, Minn. and HOLLISTON, Mass. , June 20, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc. (Nasdaq:HBIO) and the global leader in wireless physiologic
View HTML
Toggle Summary Harvard Bioscience Subsidiary Data Sciences International Launches Inhalation Exposure System
A Platform Designed by Pulmonary Experts to Provide Accurate, Real-Time Monitoring of Respiratory Endpoints ST. PAUL, Minn. and HOLLISTON, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- Data Sciences International (DSI), a subsidiary of Harvard Bioscience, Inc.
View HTML
Toggle Summary Harvard Bioscience Reports First Quarter 2018 Financial Results
-Reports GAAP and adjusted non-GAAP revenue of $26.8 million and $27.7 million , respectively, an increase of 48% and 15%, respectively- HOLLISTON, Mass. , May 02, 2018 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq:HBIO), or the Company, a global developer, manufacturer and marketer of a
View HTML